Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

AeRang Kim

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Pediatric Blood & Cancer|January 6, 2015
Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumorsSrivandana Akshintala, Leigh Marcus, Katherine E Warren, et al.
Sarcoma|February 25, 2020
Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)AeRang Kim, Yao Lu, Scott H Okuno, et al.
Plos One|March 17, 2017
Boiling histotripsy lesion characterization on a clinical magnetic resonance imaging-guided high intensity focused ultrasound systemAvinash Eranki, Navid Farr, Ari Partanen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2016
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move ForwardJoanne P Lagmay, Mark D Krailo, Ha Dang, et al.
Clinical Trials (London, England)|October 25, 2023
Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1Liny John, Gurbani Singh, Eva Dombi, et al.
Pediatric Blood & Cancer|August 12, 2021
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumorsHolly J Meany, Brigitte C Widemann, Pamela S Hinds, et al.
Sarcoma|August 21, 2019
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)Brigitte C Widemann, Yao Lu, Denise Reinke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2012
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemiaCody J Peer, Tristan M Sissung, Aerang Kim, et al.
Neuro-Oncology|February 7, 2014
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C Widemann, Eva Dombi, Andrea Gillespie, et al.
Neuro-Oncology|April 28, 2023
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromasAndrea M Gross, Eva Dombi, Pamela L Wolters, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Pediatric Blood & Cancer|January 6, 2015
Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumorsSrivandana Akshintala, Leigh Marcus, Katherine E Warren, et al.
Sarcoma|February 25, 2020
Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)AeRang Kim, Yao Lu, Scott H Okuno, et al.
Plos One|March 17, 2017
Boiling histotripsy lesion characterization on a clinical magnetic resonance imaging-guided high intensity focused ultrasound systemAvinash Eranki, Navid Farr, Ari Partanen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2016
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move ForwardJoanne P Lagmay, Mark D Krailo, Ha Dang, et al.
Clinical Trials (London, England)|October 25, 2023
Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1Liny John, Gurbani Singh, Eva Dombi, et al.
Pediatric Blood & Cancer|August 12, 2021
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumorsHolly J Meany, Brigitte C Widemann, Pamela S Hinds, et al.
Sarcoma|August 21, 2019
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)Brigitte C Widemann, Yao Lu, Denise Reinke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2012
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemiaCody J Peer, Tristan M Sissung, Aerang Kim, et al.
Neuro-Oncology|February 7, 2014
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C Widemann, Eva Dombi, Andrea Gillespie, et al.
Neuro-Oncology|April 28, 2023
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromasAndrea M Gross, Eva Dombi, Pamela L Wolters, et al.
Pageof 7